Benzinga | Mar 31, 2021 07:13AM EDT

Credit Suisse Initiates Coverage On Blueprint Medicines with Neutral Rating, Announces Price Target of $100

Credit Suisse analyst Brad Canino initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Neutral rating and announces Price Target of $100.